Literature DB >> 3011713

Protection of mouse jejunal crypt cells by WR-2721 after small doses of radiation.

E L Travis, H D Thames, S L Tucker, T L Watkins, I Kiss.   

Abstract

The ability of WR-2721 to protect jejunal crypt cells after single doses and multifractionated doses of radiation was studied. Effective dose survival curves for jejunal crypt cells were constructed over the dose range of 230 to 1600 cGy. WR-2721 was given 30 minutes before each fraction, in a regimen consisting of 200 mg/kg before the first radiation fraction, followed at 3 hr intervals by 100 mg/kg for a total of 12 drug doses for the largest number of fractions. Fractionation protocols were designed with common dose fractions in regimens with different fraction numbers, allowing a test of the hypothesis of equal effect per fraction and an estimate of the initial number of clonogens per crypt in both the drug treated and non-drug treated mice. The hypothesis of equal effect per fraction could not be rejected in either the drug or non-drug treated mice. An average number of 137 clonogens per crypt was estimated for the non-drug treated mice and 81 clonogens per crypt in the drug treated mice; the difference between these two values was not significant. The protection factor decreased with decreasing dose ranging from a high of 1.47 (95% C.L. = 1.44 to 1.50) after a single dose of 2000 cGy to a low of 1.21 (95% C.L. = 1.08 to 1.37) after 200 cGy. Analysis of the data using either the linear quadratic (LQ) or two-component (TC) model of cell survival showed that WR-2721 was not dose-modifying over the dose range tested. Analysis using the LQ model showed that both beta and alpha were modified by WR-2721, by 50% and 20% respectively. These data indicate that protection by WR-2721 can be expected to decrease with dose although there is some protection after clinically relevant doses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011713     DOI: 10.1016/0360-3016(86)90040-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  NRF2 deficiency reduces life span of mice administered thoracic irradiation.

Authors:  Elizabeth L Travis; Girish Rachakonda; Xinhui Zhou; Katrina Korhonen; Konjeti R Sekhar; Swati Biswas; Michael L Freeman
Journal:  Free Radic Biol Med       Date:  2011-06-12       Impact factor: 7.376

Review 2.  Altering the response to radiation: sensitizers and protectors.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

3.  Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.

Authors:  Konstantinos H Katsanos; Evangelos Briasoulis; Pericles Tsekeris; Anna Batistatou; Maria Bai; Christos Tolis; Antonio Capizzello; Ioannis Panelos; Vasileios Karavasilis; Dimitrios Christodoulou; Epameinondas V Tsianos
Journal:  J Exp Clin Cancer Res       Date:  2010-06-10

Review 4.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

5.  Effect of heterogeneous radio sensitivity on the survival, alpha beta ratio and biologic effective dose calculation of irradiated mammalian cell populations.

Authors:  R B Hawkins
Journal:  Clin Transl Radiat Oncol       Date:  2017-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.